Viewing StudyNCT00043706

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 11:26 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00043706
Status: COMPLETED
Last Update Posted: 2015-03-05
First Post: 2002-08-12
Brief Title: Safety Tolerability and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic Sclerosis
Sponsor: Genzyme a Sanofi Company
Organization: Sanofi
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Systemic Sclerosis
Scleroderma
Keywords: